Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | PTGFR | P43088 | 5/20 | 0.34 |
| ▸ | PTGER3 | P43115 | 3/20 | 0.34 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.34 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.34 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.34 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.33 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6085599 | 0.89 | PTGS1 (0.38) | PTGS1PTGFRPTGER3ABCB11PTGER4 | |
| SCHEMBL6084704 | 0.87 | ALDH1A1 (0.41) | PTGER3ABCB11PTGER4KDM4EMAPT | |
| SCHEMBL6085363 | 0.86 | TBXA2R (0.39) | PTGFRPTGER3PTGER4MAPK1TBXA2R | |
| SCHEMBL6086811 | 0.86 | PTGFR (0.37) | PTGS1PTGFRPTGER3ABCB11PTGER4 | |
| SCHEMBL6092808 | 0.82 | — | — | |
| SCHEMBL21959487 | 0.78 | ALDH1A1 (0.37) | MAPK1 | |
| SCHEMBL6086678 | 0.75 | ALDH1A1 (0.40) | PTGER3ABCB11PTGER4KDM4EMAPT | |
| SCHEMBL6085069 | 0.75 | TBXA2R (0.39) | PTGFRPTGER3PTGER4TBXA2RPTGER1 | |
| SCHEMBL7308118 | 0.72 | ALDH1A1 (0.46) | KDM4EMEN1MAPK1KMT2A | |
| SCHEMBL7099597 | 0.72 | KDM4E (0.44) | PTGER3PTGER4KDM4ETBXA2RPTGDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7019149-B2 | Thromboxane ligands without blood clotting side effects | ALLERGAN, INC. (US) | 2006-03-28 | — | — | US | disclosed |
| US-20050049300-A1 | Thromboxane ligands without blood clotting side effects | ALLERGAN SALES, INC. | 2005-03-03 | — | — | US | disclosed |
| US-5516791-A | VISION DEFECTS FOR TREATMENT OF HYPERTENSION OF EYES | ALLERGAN (US) | 1996-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049300-A1 | Thromboxane ligands without blood clotting side effects | OXER1, TBXA2R, OXTR | PTGS1 25/4885PTGFR 74/4885PTGER3 105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.